{
    "nct_id": "NCT06610344",
    "official_title": "Preliminary Investigation of Β-hydroxybutyrate Supplementation for Lymphoma Patients Receiving Anti-CD19 CAR T-cells",
    "inclusion_criteria": "* Age of 18 years or older\n* History of pathologically-confirmed large B-cell lymphoma (LBCL)\n* Planned treatment with a commercially available anti-CD19 CAR-T product (Yescarta or Kymriah)\n* Eligible for and with adequate organ function (investigator discretion) and performance status (ECOG PS 2 or less) for standard of care, anti-CD19 CAR-T\n* Not enrolled on a clinical trial of bridging therapy prior to CAR-T\n* Patients must have a PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra- nodal lesions in largest dimension by low-dose computerized tomography [CT] scan with FDG-uptake ≥ liver) documented prior to leukapheresis for CAR-T manufacturing\n* Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator\n* Can provide informed consent\n* Willing to comply with all study procedures and available for the duration of the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject is pregnant or breast feeding\n* History of allergy to energy drinks\n* History of inflammatory bowel disease\n* History of type 1 diabetes mellitus or requirement for insulin\n* History of chronic kidney disease with an eGFR < 30 mL/min/1.73m2\n* Additional second primary malignancy for which the subject is receiving active therapy or that will impede the ability of the investigator to assess lymphoma response",
    "miscellaneous_criteria": ""
}